Aptevo Therapeutics Inc
APVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.86M
Close$
$14.79
410.1% upside
Current Fair Value
410.1% upsideUndervalued by 410.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.86 Million |
|---|---|
| Enterprise Value | $272,777.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-87.27 |
| Beta | 1.65 |
| Outstanding Shares | 1,196,364 |
Return
| Return on Equity | -487.63% |
|---|---|
| Return on Assets | -202.89% |
| Return on Invested Capital | -289.07% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | -0.52 |
| Price to Sales | -2.9 |
| Price to Book Ratio | 0.58 |
| Enterprise Value to Revenue | -1.24 |
| Enterprise Value to EBIT | -0.01 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 15.43 |
| Debt to Equity | 0.7 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-6.01
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-5.67
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.07%▲ 3.15% |
|---|---|
| Total Invested | $229,654▲ 20.01% |
| Investors Holding | 9▼ 1.00% |
ESG Score
No data
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO6...